Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
RFS/DFS | 0.30 [0.17, 0.52] | | < 1 | | 23% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | important | - |
safety endpoints 00 |
AE leading to death (grade 5) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
AE leading to treatment discontinuation (any grade) | 18.39 [5.56, 60.77] | | < 1 | | 47% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
AE leading to treatment discontinuation (grade 3-4) | 19.58 [4.47, 85.82] | | < 1 | | 45% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
SAE (any grade) | 4.08 [2.31, 7.19] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
SAE (grade 3-4) | 5.29 [2.15, 13.00] | | < 1 | | 53% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
STRAE (any grade) | 12.43 [2.18, 70.81] | | < 1 | | 76% | 2 studies (2/-) | 0.2 % | low | not evaluable | high | non important | - |
STRAE (grade 3-4) | 14.97 [0.88, 254.99] | | < 1 | | 74% | 2 studies (2/-) | 3.2 % | low | not evaluable | high | non important | - |
TRAE (any grade) | 10.70 [2.57, 44.58] | | < 1 | | 41% | 2 studies (2/-) | 0.1 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) | 14.96 [2.66, 84.03] | | < 1 | | 80% | 2 studies (2/-) | 0.1 % | low | not evaluable | high | non important | - |
TRAE leading to death (grade 5) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
TRAE leading to discontinuation (any grade) | 24.36 [3.72, 159.46] | | < 1 | | 65% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
TRAE leading to discontinuation (grade 3-4) | 24.18 [2.93, 199.61] | | < 1 | | 55% | 2 studies (2/-) | 0.2 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Acute kidney injury TRAE (grade 3-4) | 1.96 [0.18, 21.95] | | < 1 | | 0% | 2 studies (2/-) | 29.4 % | low | not evaluable | high | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 1.96 [0.18, 21.95] | | < 1 | | 0% | 2 studies (2/-) | 29.4 % | low | not evaluable | high | non important | - |
Alopecia TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Anaemia TRAE (grade 3-4) | 1.96 [0.18, 21.95] | | < 1 | | 0% | 2 studies (2/-) | 29.4 % | low | not evaluable | high | non important | - |
Arthralgia TRAE (grade 3-4) | 0.41 [0.04, 4.76] | | < 1 | | 0% | 2 studies (2/-) | 76.0 % | low | not evaluable | high | non important | - |
Blood and lymphatic system disorders TRAE (grade 3-4) | 1.44 [0.11, 19.02] | | < 1 | | 0% | 2 studies (2/-) | 39.2 % | low | not evaluable | high | non important | - |
Blood creatinine increased TRAE (grade 3-4) | 0.93 [0.02, 47.58] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Chills TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Colitis TRAE (grade 3-4) | 6.11 [0.72, 51.62] | | < 1 | | 0% | 2 studies (2/-) | 4.9 % | low | not evaluable | high | non important | - |
Cough TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Diabetes TRAE (grade 3-4) | 0.65 [0.05, 8.65] | | < 1 | | 0% | 2 studies (2/-) | 62.5 % | low | not evaluable | high | non important | - |
Diarrhoea TRAE (grade 3-4) | 1.30 [0.15, 11.32] | | < 1 | | 0% | 2 studies (2/-) | 40.7 % | low | not evaluable | high | non important | - |
Dizziness TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Dry skin TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Dysgeusia TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Dyspepsia TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Dyspnoea TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Ear and labyrinth disorders TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Endocrine disorders TRAE (grade 3-4) | 6.83 [1.19, 39.30] | | < 1 | | 0% | 2 studies (2/-) | 1.6 % | low | not evaluable | high | non important | - |
Eye disorders TRAE (grade 3-4) | 1.96 [0.18, 21.95] | | < 1 | | 0% | 2 studies (2/-) | 29.4 % | low | not evaluable | high | non important | - |
Fatigue TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Gastritis TRAE (grade 3-4) | 4.00 [0.44, 36.34] | | < 1 | | 0% | 2 studies (2/-) | 11.1 % | low | not evaluable | high | non important | - |
Gastrointestinal disorders TRAE (grade 3-4) | 11.58 [2.10, 63.74] | | < 1 | | 0% | 2 studies (2/-) | 0.3 % | low | not evaluable | high | non important | - |
General disorders and administration site conditions TRAE (grade 3-4) | 4.00 [0.44, 36.34] | | < 1 | | 0% | 2 studies (2/-) | 11.1 % | low | not evaluable | high | non important | - |
Headache TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Hepatitis TRAE (grade 3-4) | 4.55 [1.09, 19.08] | | < 1 | | 0% | 2 studies (2/-) | 1.9 % | low | not evaluable | high | non important | - |
Hepatobiliary disorders TRAE (grade 3-4) | 10.17 [2.60, 39.71] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
Hypertension TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 6.11 [0.72, 51.62] | | < 1 | | 0% | 2 studies (2/-) | 4.9 % | low | not evaluable | high | non important | - |
Hypophysitis TRAE (grade 3-4) | 0.65 [0.05, 8.65] | | < 1 | | 0% | 2 studies (2/-) | 62.5 % | low | not evaluable | high | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Increase AST TRAE (grade 3-4) | 4.46 [1.07, 18.60] | | < 1 | | 12% | 2 studies (2/-) | 2.0 % | low | not evaluable | high | non important | - |
Increased ALT TRAE (grade 3-4) | 8.10 [1.94, 33.82] | | < 1 | | 15% | 2 studies (2/-) | 0.2 % | low | not evaluable | high | non important | - |
Increased lipase level TRAE (grade 3-4) | 2.86 [1.07, 7.62] | | < 1 | | 0% | 2 studies (2/-) | 1.8 % | low | not evaluable | high | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Leucopenia TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Maculopapular rash TRAE (grade 3-4) | 1.96 [0.18, 21.95] | | < 1 | | 0% | 2 studies (2/-) | 29.4 % | low | not evaluable | high | non important | - |
Metabolism and nutrition disorders TRAE (grade 3-4) | 1.30 [0.15, 11.32] | | < 1 | | 0% | 2 studies (2/-) | 40.7 % | low | not evaluable | high | non important | - |
Musculoskeletal and connective tissue disorders TRAE (grade 3-4) | 0.31 [0.03, 3.39] | | < 1 | | 0% | 2 studies (2/-) | 83.0 % | low | not evaluable | high | non important | - |
Myalgia TRAE (grade 3-4) | 0.65 [0.05, 8.65] | | < 1 | | 0% | 2 studies (2/-) | 62.5 % | low | not evaluable | high | non important | - |
Myositis TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Nausea TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Nervous system disorders TRAE (grade 3-4) | 0.78 [0.11, 5.64] | | < 1 | | 0% | 2 studies (2/-) | 59.7 % | low | not evaluable | high | non important | - |
Neutropenia TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Pancreatitis TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Paraesthesia TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 1.96 [0.18, 21.95] | | < 1 | | 0% | 2 studies (2/-) | 29.4 % | low | not evaluable | high | non important | - |
Pneumonitis TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Pruritus TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Pyrexia TRAE (grade 3-4) | 4.00 [0.44, 36.34] | | < 1 | | 0% | 2 studies (2/-) | 11.1 % | low | not evaluable | high | non important | - |
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Sarcoidosis TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 3.96 [0.64, 24.63] | | < 1 | | 0% | 2 studies (2/-) | 7.1 % | low | not evaluable | high | non important | - |
Stomatitis TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 1.96 [0.18, 21.95] | | < 1 | | 0% | 2 studies (2/-) | 29.4 % | low | not evaluable | high | non important | - |
Thyroiditis TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Uveitis TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Vitiligo TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Vomiting TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |
Weight decreased TRAE (grade 3-4) | 0.97 [0.06, 15.73] | | < 1 | | 0% | 2 studies (2/-) | 50.8 % | low | not evaluable | high | non important | - |